• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?

作者信息

Mehta Puja, Porter Joanna C, Chambers Rachel C, Isenberg David A, Reddy Venkat

机构信息

Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK.

Department of Rheumatology, University College London Hospital, London NW1 2PG, UK.

出版信息

Lancet Rheumatol. 2020 Oct;2(10):e589-e590. doi: 10.1016/S2665-9913(20)30270-8. Epub 2020 Jul 31.

DOI:10.1016/S2665-9913(20)30270-8
PMID:33521659
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7836835/
Abstract
摘要

相似文献

1
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?利妥昔单抗在新冠疫情中对B细胞的清除作用：我们目前的情况如何？
Lancet Rheumatol. 2020 Oct;2(10):e589-e590. doi: 10.1016/S2665-9913(20)30270-8. Epub 2020 Jul 31.
2
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.英国风湿和肌肉骨骼疾病患者在利妥昔单抗治疗期间的严重急性呼吸综合征冠状病毒2突破性感染及中重度结局预测：一项单中心队列研究
Lancet Rheumatol. 2023 Feb;5(2):e88-e98. doi: 10.1016/S2665-9913(23)00004-8. Epub 2023 Jan 10.
3
Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab.病例报告：用利妥昔单抗治疗的天疱疮患者 COVID-19 后完全快速康复。
Front Immunol. 2021 Apr 16;12:665522. doi: 10.3389/fimmu.2021.665522. eCollection 2021.
4
SARS-CoV-2 Infection in Pemphigus Vulgaris Two Weeks after Rituximab Therapy with Total Recovery: A Case Report.天疱疮患者利妥昔单抗治疗 2 周后发生 SARS-CoV-2 感染并完全康复：1 例病例报告。
Acta Dermatovenerol Croat. 2023 Dec;31(3):156-157.
5
Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia.在2019冠状病毒病大流行期间使用免疫抑制疗法治疗天疱疮的考量，重点关注利妥昔单抗：来自澳大利亚单一中心经验的病例报告
Front Med (Lausanne). 2023 Mar 14;10:1149742. doi: 10.3389/fmed.2023.1149742. eCollection 2023.
6
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.FcγRIIIa基因分型与利妥昔单抗治疗系统性红斑狼疮时B细胞耗竭程度的关系。
Arthritis Rheum. 2003 Feb;48(2):455-9. doi: 10.1002/art.10764.
7
Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG.利妥昔单抗在不同基质中体外介导食蟹猴B细胞的耗竭：IgG的可能抑制作用
Int Immunopharmacol. 2004 Aug;4(8):1117-24. doi: 10.1016/j.intimp.2004.04.015.
8
Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion.利妥昔单抗治疗后外周血B淋巴细胞耗竭期间肾病综合征的复发
Clin Exp Nephrol. 2018 Feb;22(1):110-116. doi: 10.1007/s10157-017-1415-8. Epub 2017 Apr 22.
9
Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.类风湿关节炎中低剂量利妥昔单抗：疗效取决于B细胞耗竭程度。
Arthritis Rheum. 2011 Mar;63(3):603-8. doi: 10.1002/art.30152.
10
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.高灵敏度B细胞分析可预测类风湿关节炎患者对利妥昔单抗治疗的反应。
Arthritis Rheum. 2008 Oct;58(10):2993-9. doi: 10.1002/art.23902.

引用本文的文献

1
[Current Status of Passive Immunization Against COVID in Respiratory Patients].[呼吸道疾病患者中新冠被动免疫的现状]
Open Respir Arch. 2025 Jan 17;7(2):100398. doi: 10.1016/j.opresp.2025.100398. eCollection 2025 Apr-Jun.
2
Antibody response to four doses of SARS-CoV-2 vaccine in rare autoimmune rheumatic diseases: an observational study.罕见自身免疫性风湿病患者对四剂严重急性呼吸综合征冠状病毒2疫苗的抗体反应：一项观察性研究
Rheumatol Adv Pract. 2023 Nov 11;7(3):rkad097. doi: 10.1093/rap/rkad097. eCollection 2023.
3
COVID-19 in immunocompromised patients after hematopoietic stem cell transplantation: a pilot study.造血干细胞移植后免疫功能低下患者的新型冠状病毒肺炎：一项初步研究。
Blood Sci. 2024 Jan 25;6(2):e00183. doi: 10.1097/BS9.0000000000000183. eCollection 2024 Apr.
4
Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion.康复期血浆治疗B细胞耗竭患者长期新冠病毒感染的疗效
Life (Basel). 2023 May 27;13(6):1266. doi: 10.3390/life13061266.
5
The clinical impact of COVID-19 on patients with cancer in British Columbia: An observational study.COVID-19对不列颠哥伦比亚省癌症患者的临床影响：一项观察性研究。
Heliyon. 2022 Dec;8(12):e12140. doi: 10.1016/j.heliyon.2022.e12140. Epub 2022 Dec 7.
6
COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature.肉芽肿性多血管炎中 COVID-19 的病程：单中心经验及文献复习。
Turk J Med Sci. 2022 Aug;52(4):899-909. doi: 10.55730/1300-0144.5389. Epub 2022 Aug 10.
7
Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination.接种 SARS-CoV-2 疫苗后罕见自身免疫性风湿病患者的体液和细胞免疫。
Rheumatology (Oxford). 2023 Jun 1;62(6):2294-2303. doi: 10.1093/rheumatology/keac574.
8
Association of Disease-Modifying Therapies with COVID-19 Susceptibility and Severity in Patients with Multiple Sclerosis: A Systematic Review and Network Meta-Analysis.疾病修饰疗法与多发性硬化症患者对 COVID-19 的易感性及严重程度的关联：一项系统评价与网状 Meta 分析
Mult Scler Int. 2022 Sep 21;2022:9388813. doi: 10.1155/2022/9388813. eCollection 2022.
9
Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.鉴定已灭活的 COVID-19 恢复期血浆的特性及在输注患者中的反应。
Transfusion. 2022 Oct;62(10):1997-2011. doi: 10.1111/trf.17083. Epub 2022 Sep 5.
10
Clinical course of idiopathic inflammatory myopathies in COVID-19 pandemic: a single-center experience.2019年冠状病毒病大流行期间特发性炎性肌病的临床病程：单中心经验
Future Virol. 2022 May. doi: 10.2217/fvl-2021-0146. Epub 2022 Jun 15.

本文引用的文献

1
Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?COVID-19 与抗 MDA5 综合征的相似之处：我们能从中吸取哪些经验以改善治疗？
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01618-2020. Print 2020 Sep.
2
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
3
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.利妥昔单抗用于新冠疫情期间的肉芽肿性多血管炎：一例重症肺炎病例的经验教训
Ann Rheum Dis. 2021 Jan;80(1):e10. doi: 10.1136/annrheumdis-2020-217549. Epub 2020 Apr 20.
4
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.新型冠状病毒肺炎患者的凝血障碍与抗磷脂抗体
N Engl J Med. 2020 Apr 23;382(17):e38. doi: 10.1056/NEJMc2007575. Epub 2020 Apr 8.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.